Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Peter J. O'Brien, Rajeev Ramanathan, Jonathan M. Yingling, Jose Baselga, Mace L. Rothenberg, Michael A Carducci, Thomas Daly, Dorothy Adcock, Michael Lahn

Research output: Contribution to journalArticle

Abstract

Transforming growth factor beta (TGFβ) plays an important role in cancer, but accurate measurement of circulating TGFβ is complicated by the high TGFβ content of platelets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosinedipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGFβ could be subdivided into groups with or without evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a better determination of a patient's TGFβ status, and may improve classification of patients with oncologic disease.

Original languageEnglish (US)
Pages (from-to)563-569
Number of pages7
JournalBiologics: Targets and Therapy
Volume2
Issue number3
StatePublished - 2008

Fingerprint

Transforming Growth Factor beta
Neoplasm Metastasis
Neoplasms
Theophylline
Citric Acid
Platelet Activation
Blood Platelets
Tissue Donors

Keywords

  • Biomarker
  • Cancer
  • CTAD
  • TGFβ

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

O'Brien, P. J., Ramanathan, R., Yingling, J. M., Baselga, J., Rothenberg, M. L., Carducci, M. A., ... Lahn, M. (2008). Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases. Biologics: Targets and Therapy, 2(3), 563-569.

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases. / O'Brien, Peter J.; Ramanathan, Rajeev; Yingling, Jonathan M.; Baselga, Jose; Rothenberg, Mace L.; Carducci, Michael A; Daly, Thomas; Adcock, Dorothy; Lahn, Michael.

In: Biologics: Targets and Therapy, Vol. 2, No. 3, 2008, p. 563-569.

Research output: Contribution to journalArticle

O'Brien, PJ, Ramanathan, R, Yingling, JM, Baselga, J, Rothenberg, ML, Carducci, MA, Daly, T, Adcock, D & Lahn, M 2008, 'Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases', Biologics: Targets and Therapy, vol. 2, no. 3, pp. 563-569.
O'Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci MA et al. Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases. Biologics: Targets and Therapy. 2008;2(3):563-569.
O'Brien, Peter J. ; Ramanathan, Rajeev ; Yingling, Jonathan M. ; Baselga, Jose ; Rothenberg, Mace L. ; Carducci, Michael A ; Daly, Thomas ; Adcock, Dorothy ; Lahn, Michael. / Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases. In: Biologics: Targets and Therapy. 2008 ; Vol. 2, No. 3. pp. 563-569.
@article{2757bc4226ad48ca9571849cd276ce78,
title = "Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases",
abstract = "Transforming growth factor beta (TGFβ) plays an important role in cancer, but accurate measurement of circulating TGFβ is complicated by the high TGFβ content of platelets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosinedipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGFβ could be subdivided into groups with or without evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a better determination of a patient's TGFβ status, and may improve classification of patients with oncologic disease.",
keywords = "Biomarker, Cancer, CTAD, TGFβ",
author = "O'Brien, {Peter J.} and Rajeev Ramanathan and Yingling, {Jonathan M.} and Jose Baselga and Rothenberg, {Mace L.} and Carducci, {Michael A} and Thomas Daly and Dorothy Adcock and Michael Lahn",
year = "2008",
language = "English (US)",
volume = "2",
pages = "563--569",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

AU - O'Brien, Peter J.

AU - Ramanathan, Rajeev

AU - Yingling, Jonathan M.

AU - Baselga, Jose

AU - Rothenberg, Mace L.

AU - Carducci, Michael A

AU - Daly, Thomas

AU - Adcock, Dorothy

AU - Lahn, Michael

PY - 2008

Y1 - 2008

N2 - Transforming growth factor beta (TGFβ) plays an important role in cancer, but accurate measurement of circulating TGFβ is complicated by the high TGFβ content of platelets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosinedipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGFβ could be subdivided into groups with or without evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a better determination of a patient's TGFβ status, and may improve classification of patients with oncologic disease.

AB - Transforming growth factor beta (TGFβ) plays an important role in cancer, but accurate measurement of circulating TGFβ is complicated by the high TGFβ content of platelets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosinedipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGFβ could be subdivided into groups with or without evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a better determination of a patient's TGFβ status, and may improve classification of patients with oncologic disease.

KW - Biomarker

KW - Cancer

KW - CTAD

KW - TGFβ

UR - http://www.scopus.com/inward/record.url?scp=77954176730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954176730&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 563

EP - 569

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

IS - 3

ER -